cysteamine-s-phosphate profile

Cystaphos: Proposed as an adjuvant to cancer chemotherapy; may have radiation protective properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cysteamine S-phosphate(2-) : An organic phosphorothioate anion that is the conjugate base of cysteamine S-phosphate, obtained by deprotonation of the two free thiophosohate OH groups and protonation of the amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cysteamine S-phosphate : An organic thiophosphate that is the S-phospho derivative of cysteamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	25201178
CHEBI ID	74631
MeSH ID	M0067700

Synonym
cystaphos
phosphorothioic acid, s-(2-aminoethyl) ester
2-aminoethanethiol dihydrogen phosphate (ester)
cysteamine s-phosphate
CHEBI:74631
cysteamine s-phosphate(2-)
s-(2-azaniumylethyl) phosphorothioate
2-phosphonatosulfanylethylazanium

Excerpt	Reference	Relevance
" It has been suggested that cysteamine bitartrate and phosphocysteamine are better tolerated and may have a better bioavailability than cysteamine hydrochloride."	( A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Chaumet-Riffaud, P; Daurat, V; Funck-Brentano, C; Tennezé, L; Tibi, A, 1999)	0.3
"We compared the pharmacokinetics and tolerance of these three formulations of cysteamine in 18 healthy adult male volunteers in a double-blind, latin-square, three-period, single oral dose cross-over relative bioavailability study."	( A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Chaumet-Riffaud, P; Daurat, V; Funck-Brentano, C; Tennezé, L; Tibi, A, 1999)	0.3

Class	Description
organic phosphorothioate anion	An organic anion obtained by deprotonation of any organic phosphorothioate.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (50.00)	18.7374
1990's	6 (33.33)	18.2507
2000's	2 (11.11)	29.6817
2010's	1 (5.56)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.04%)	5.53%
Reviews	4 (8.16%)	6.00%
Case Studies	2 (4.08%)	4.05%
Observational	0 (0.00%)	0.25%
Other	42 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
5-methoxytryptamine 5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.	1.95	1	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	1.95	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2.36	2	0	aziridines
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	6.88	8	1	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
beta-mercaptopropylamine beta-mercaptopropylamine: RN given refers to cpd with isomeric designation; structure	1.95	1	0
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.92	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
wr 1065 WR-1065 : An alkanethiol that is the N-3-aminopropyl derivative of cysteamine. Used as the S-phosphorylated prodrug, amifostine, for cytoprotection in cancer chemotherapy and radiotherapy.	1.95	1	0	alkanethiol; diamine	antioxidant; drug metabolite; radiation protective agent
palmitoyl coenzyme a Palmitoyl Coenzyme A: A fatty acid coenzyme derivative which plays a key role in fatty acid oxidation and biosynthesis.. palmitoyl-CoA : A long-chain fatty acyl-CoA resulting from the formal condensation of the carboxy group of hexadecanoic acid with the thiol group of coenzyme A.	2.92	1	0	11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate	Escherichia coli metabolite; mouse metabolite
cystine [no description available]	5.08	5	0

Condition	Relationship Strength	Studies	Trials
Degenerative Diseases, Central Nervous System [description not available]	2.07	1	0
Adult Neuronal Ceroid Lipofuscinosis [description not available]	3.35	2	0
Neuronal Ceroid-Lipofuscinoses A group of severe neurodegenerative diseases characterized by intracellular accumulation of autofluorescent wax-like lipid materials (CEROID; LIPOFUSCIN) in neurons. There are several subtypes based on mutations of the various genes, time of disease onset, and severity of the neurological defects such as progressive DEMENTIA; SEIZURES; and visual failure.	3.35	2	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.07	1	0
Acidosis, Renal Tubular, Type I [description not available]	2.01	1	0
Cystine Diathesis [description not available]	5.19	7	0
Failure to Thrive A condition of substandard growth or diminished capacity to maintain normal function.	2.01	1	0
Rachitis [description not available]	2.01	1	0
Acidosis, Renal Tubular A group of genetic disorders of the KIDNEY TUBULES characterized by the accumulation of metabolically produced acids with elevated plasma chloride, hyperchloremic metabolic ACIDOSIS. Defective renal acidification of URINE (proximal tubules) or low renal acid excretion (distal tubules) can lead to complications such as HYPOKALEMIA, hypercalcinuria with NEPHROLITHIASIS and NEPHROCALCINOSIS, and RICKETS.	2.01	1	0
Cystinosis A metabolic disease characterized by the defective transport of CYSTINE across the lysosomal membrane due to mutation of a membrane protein cystinosin. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. In the KIDNEY, nephropathic cystinosis is a common cause of RENAL FANCONI SYNDROME.	5.19	7	0
Adult Fanconi Syndrome [description not available]	1.95	1	0
Kidney Stones [description not available]	1.99	1	0
Kidney Calculi Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.	1.99	1	0
Emesis [description not available]	4.69	2	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	4.69	2	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2	1	0
Eye Disorders [description not available]	2.88	1	0
Eye Diseases Diseases affecting the eye.	2.88	1	0
Cancer of Ovary [description not available]	1.96	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1.96	1	0

cysteamine-s-phosphate

Description

Cross-References

Synonyms (8)

Research Excerpts

Bioavailability

Drug Classes (1)

Research

Studies (18)

Study Types